Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer

Inclusion Criteria: * Pathologically/histologically confirmed NSCLC * Advance NSCLC (stage IIIB w/ effusion, stage IV, or recurrent disease) * Measurable disease * Two prior systemic anti-cancer (cytotoxic or biologic) regimens for advanced/metastatic disease, including one (1) platinum-based chemotherapy * Prior treatment allowed if side effects have resolved and 3 weeks has passed since last dose of treatment (1 week for palliative radiation therapy) * ECOG performance status 0, 1, or 2 * Patients with brain metastases are allowed, if clinically stable after treatment * Normal liver, kidney, and marrow function * 18 years of age or older * Negative pregnancy test for women of child-bearing potential. * Life expectancy 3 months or more * No concurrent use of other antitumor agents Exclusion Criteria: * Prior therapy with vorinostat, HDAC inhibitors, or bortezomib * Pre-existing neuropathy grade \>/= 2 * Myocardial infarction within 6 months prior to enrollment or have NY Heart Association Class III or Class IV heart failure * Have taken valproic acid \</= 4 weeks prior to enrollment * Previous or current malignancies of other histologies within the past 5 years, except cervical carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the skin * Hypersensitivity to bortezomib, boron, or mannitol * Serious medical or psychiatric illness likely to interfere with participation in the clinical study * Pregnant women * HIV positive patients * Hepatitis infection (HCV or HBV) patients